Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/35608
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Flynn J.K. | en |
dc.contributor.author | Morand, Eric | en |
dc.contributor.author | Dankers W. | en |
dc.date.accessioned | 2021-05-14T12:02:19Z | en |
dc.date.available | 2021-05-14T12:02:19Z | en |
dc.date.copyright | 2019 | en |
dc.date.created | 20190727 | en |
dc.date.issued | 2019-07-27 | en |
dc.identifier.citation | Frontiers in Immunology. 10 (JULY) (no pagination), 2019. Article Number: 1684. Date of Publication: 2019. | en |
dc.identifier.issn | 1664-3224 (electronic) | en |
dc.identifier.uri | https://repository.monashhealth.org/monashhealthjspui/handle/1/35608 | en |
dc.description.abstract | Glucocorticoids (GC) are used globally to treat autoimmune and inflammatory disorders. Their anti-inflammatory actions are mainly mediated via binding to the glucocorticoid receptor (GR), creating a GC/GR complex, which acts in both the cytoplasm and nucleus to regulate the transcription of a host of target genes. As a result, signaling pathways such as NF-kappaB and AP-1 are inhibited, and cell activation, differentiation and survival and cytokine and chemokine production are suppressed. However, the gene regulation by GC can also cause severe side effects in patients. Systemic lupus erythematosus (SLE or lupus) is a multisystem autoimmune disease, characterized by a poorly regulated immune response leading to chronic inflammation and dysfunction of multiple organs, for which GC is the major current therapy. Long-term GC use, however, can cause debilitating adverse consequences for patients including diabetes, cardiovascular disease and osteoporosis and contributes to irreversible organ damage. To date, there is no alternative treatment which can replicate the rapid effects of GC across multiple immune cell functions, effecting disease control during disease flares. Research efforts have focused on finding alternatives to GC, which display similar immunoregulatory actions, without the devastating adverse metabolic effects. One potential candidate is the glucocorticoid-induced leucine zipper (GILZ). GILZ is induced by low concentrations of GC and is shown to mimic the action of GC in several inflammatory processes, reducing immunity and inflammation in in vitro and in vivo studies. Additionally, GILZ has, similar to the GC-GR complex, the ability to bind to both NF-kappaB and AP-1 as well as DNA directly, to regulate immune cell function, while potentially lacking the GC-related side effects. Importantly, in SLE patients GILZ is under-expressed and correlates negatively with disease activity, suggesting an important regulatory role of GILZ in SLE. Here we provide an overview of the actions and use of GC in lupus, and discuss whether the regulatory mechanisms of GILZ could lead to the development of a novel therapeutic for lupus. Increased understanding of the mechanisms of action of GILZ, and its ability to regulate immune events leading to lupus disease activity has important clinical implications for the development of safer anti-inflammatory therapies.Copyright © 2019 Flynn, Dankers and Morand. | en |
dc.language | en | en |
dc.language | English | en |
dc.publisher | Frontiers Media S.A. (E-mail: info@frontiersin.org) | en |
dc.relation.ispartof | Frontiers in Immunology | en |
dc.title | Could GILZ be the answer to glucocorticoid toxicity in lupus?. | en |
dc.type | Review | en |
dc.identifier.affiliation | Rheumatology | - |
dc.type.studyortrial | Review article (e.g. literature review, narrative review) | - |
dc.identifier.doi | http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.3389/fimmu.2019.01684 | en |
dc.publisher.place | Switzerland | en |
dc.identifier.pubmedid | 31379872 [http://www.ncbi.nlm.nih.gov/pubmed/?term=31379872] | en |
dc.identifier.source | 628553266 | en |
dc.identifier.institution | (Flynn, Dankers, Morand) School of Clinical Sciences at Monash Health, Monash University, Melbourne, VIC, Australia | en |
dc.description.address | J.K. Flynn, School of Clinical Sciences at Monash Health, Monash University, Melbourne, VIC, Australia. E-mail: jacqueline.flynn@monash.edu | en |
dc.description.publicationstatus | Embase | en |
dc.rights.statement | Copyright 2019 Elsevier B.V., All rights reserved. | en |
dc.subect.keywords | GILZ Glucorticoids Lupus (SLE) Regulation Transcription factor Treatment | en |
dc.identifier.authoremail | Flynn J.K.; jacqueline.flynn@monash.edu Morand E.F.; eric.morand@monash.edu | en |
item.cerifentitytype | Publications | - |
item.fulltext | No Fulltext | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.grantfulltext | none | - |
item.openairetype | Review | - |
crisitem.author.dept | Rheumatology | - |
crisitem.author.dept | Centre for Inflammatory Diseases at Monash Health | - |
Appears in Collections: | Articles |
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.